



## 2nd SCI / RSC Fibrosis Medicinal Chemistry Symposium

Friday 10 November 2017

SCI, London, UK



ROYAL SOCIETY  
OF CHEMISTRY

BIOLOGICAL AND  
MEDICINAL  
CHEMISTRY  
SECTOR

Organised by SCI's Fine Chemicals Group and RSC's  
Biological and Medicinal Chemistry Sector



**SCI**

where science meets business

# 2nd SCI / RSC Fibrosis Medicinal Chemistry Symposium

Friday 10 November 2017, SCI, London, UK

## Synopsis

Fibrosis disease, the result of a dysregulated wound healing process after injury that can have a high mortality rate, manifests in many areas of the body. With two drugs recently reaching marketed status for Idiopathic Pulmonary Fibrosis (IPF), there is continued growth and investment to identify new treatments, including for other conditions, such as liver fibrosis and diabetic nephropathy. Fibrosis has complex disease pathology and greater knowledge of mechanisms is sought. This symposium will cover drug discovery and medicinal chemistry aspects of fibrotic conditions from leading experts in the field.

## Exhibition

An exhibition will run alongside the conference during refreshment breaks. For further information and prices please email [conferences@soci.org](mailto:conferences@soci.org).

## Registration

To view the full programme and register for the event, please visit: [www.soci.org/events](http://www.soci.org/events). Rates are SCI/RSC Members £110, Non-Members £150, SCI/RSC Student Member £50

## Posters

Send one A4 page or 300 words indicating title, authors and preference for presentation option [conferences@soci.org](mailto:conferences@soci.org) with "Fibrosis - poster submission" in the subject line by **Monday 30 October**. There are a limited number of bursaries available. Priority will be given to those presenting a poster.

## Sponsors



## Programme

- ▶ **9.30-10.00: Registration**
- ▶ **An overview of liver and kidney fibrosis**  
Dr Fiona Oakley, University of Newcastle, UK
- ▶ **Idiopathic pulmonary fibrosis: Impact of current treatments, limitations and opportunities**  
Dr Hannah Woodcock, University College London, UK
- ▶ **Discovery and development of galectin-3 ligand mimetics as anti-fibrosis compounds**  
Prof Ulf Nilsson, Lund University, Sweden
- ▶  **$\alpha$ v integrin modulators for fibrosis and the profile of an  $\alpha$ v $\beta$ 6 clinical candidate**  
Dr Simon Macdonald, GlaxoSmithKline, UK
- ▶ **Discovery of GLPG1690: a first-in-class autotoxin inhibitor in clinical development for the treatment of idiopathic pulmonary fibrosis**  
Dr Nicolas Desroy, Galapagos, France
- ▶ **Porcupine inhibitors as anti-fibrotic therapies**  
Dr Cliff Jones, Redx Pharma Plc, UK
- ▶ **Cannabinoid Receptor (CB1R) based dual-target approaches for the treatment of fibrotic conditions**  
Dr Malliga Iyer, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, USA
- ▶ **Transglutaminase 2: an ideal therapeutic target for the treatment of fibrosis using small molecule inhibitors**  
Prof Martin Griffin, Aston University, UK
- ▶ **17.00-18.00: Wine reception, posters and networking**

## For further details:

14/15 Belgrave Square,  
London, SW1X 8PS

T: +44 (0) 20 7598 1561

E: [conferences@soci.org](mailto:conferences@soci.org)

W: [www.soci.org](http://www.soci.org)

